Citation Impact
Citing Papers
Modulation of immune cell reactivity with cis -binding Siglec agonists
2021 StandoutNobel
A Small-Molecule Modulator of Poly-α2,8-Sialic Acid Expression on Cultured Neurons and Tumor Cells
2001 StandoutScienceNobel
Pathological α-Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice
2012 StandoutScience
α-Synuclein Promotes SNARE-Complex Assembly in Vivo and in Vitro
2010 StandoutScienceNobel
Role of Genotype in the Cycle of Violence in Maltreated Children
2002 StandoutScience
Parkinson-like syndrome induced by continuous MPTP infusion: Convergent roles of the ubiquitin-proteasome system and α-synuclein
2005 StandoutNobel
Mediation of Poly(ADP-Ribose) Polymerase-1-Dependent Cell Death by Apoptosis-Inducing Factor
2002 StandoutScience
Onset and Progression in Inherited ALS Determined by Motor Neurons and Microglia
2006 StandoutScience
The Role of Oxidative Stress in Parkinson's Disease
2013
The Role of Innate and Adaptive Immunity in Parkinson's Disease
2013
Astrocytic expression of Parkinson's disease-related A53T α-synuclein causes neurodegeneration in mice
2010
Neuroinflammation mediated by IL-1β increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease
2008
Limelight on Alpha-Synuclein: Pathological and Mechanistic Implications in Neurodegeneration
2013
Neuroinflammation in Parkinson's disease: a target for neuroprotection?
2009 Standout
Interleukin-2 but not basic fibroblast growth factor is elevated in parkinsonian brain
1996
Molecular mechanisms of L-DOPA-induced dyskinesia
2008
Parkinson disease
2017 Standout
Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease
2009
Proteasomal Inhibition by α-Synuclein Filaments and Oligomers
2004
The Ubiquitin Proteasome System in Neurodegenerative Diseases
2003 StandoutNobel
Monoamine Oxidase B Inhibitors for the Treatment of Parkinsonʼs Disease
2011
Dose- and time-dependent α-synuclein aggregation induced by ferric iron in SK-N-SH cells
2010
Short communication Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease
2009
Mechanisms Underlying Inflammation in Neurodegeneration
2010 Standout
Microglia-mediated neurotoxicity: uncovering the molecular mechanisms
2006 Standout
Oxidative Stress Hypothesis in Alzheimer's Disease
1997 Standout
Pathology of Parkinson’s disease
1991
Interaction of polymorphisms in the genes encoding interleukin‐6 and estrogen receptor beta on the susceptibility to Parkinson's disease
2005
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
1998 StandoutNature
The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease
2011
Unbiased Approaches to Biomarker Discovery in Neurodegenerative Diseases
2014
Mitochondrial dysfunction, apoptotic cell death, and Alzheimer’s disease
2003
Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease
2013
PDD‐Short Screen: A brief cognitive test for screening dementia in Parkinson's disease
2010
Protective action of the peroxisome proliferator‐activated receptor‐γ agonist pioglitazone in a mouse model of Parkinson's disease
2002
Transforming growth factor-β1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease
1995
Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo
2009
Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains
1989
p53 protein, interferon-γ, and NF-κB levels are elevated in the parkinsonian brain
2006
The Expression of Key Oxidative Stress-Handling Genes in Different Brain Regions in Alzheimer's Disease
1998
Amyloid‐β‐induced toxicity of primary neurons is dependent upon differentiation‐associated increases in tau and cyclin‐dependent kinase 5 expression
2003
Neurotransmitter Release: The Last Millisecond in the Life of a Synaptic Vesicle
2013 StandoutNobel
Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease
2003
Tumor necrosis factor-alpha receptor ablation in a chronic MPTP mouse model of Parkinson's disease
2004
Of Pesticides and Men: a California Story of Genes and Environment in Parkinson’s Disease
2016
Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease
2000
Overdependence on degraded gist memory in Alzheimer's disease.
2006 Standout
Part II: α-synuclein and its molecular pathophysiological role in neurodegenerative disease
2003
Zinc takes the center stage: its paradoxical role in Alzheimer’s disease
2003
Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure
1999
Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism
2005
Clinical and biochemical correlates of insoluble α-synuclein in dementia with Lewy bodies
2006
Mice Deficient in Golf Are Anosmic
1998 StandoutNobel
Various proteins from rat brain, specifically and irreversibly labeled by [3H]flunitrazepam, are distinct α-subunits of the GABA-benzodiazepine receptor complex
1988
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
1991 Standout
Mitochondria: In Sickness and in Health
2012 Standout
Prefrontal and Striatal Volumes in Monozygotic Twins Concordant and Discordant for Schizophrenia
2010
Nrf2-induced antioxidant protection: A promising target to counteract ROS-mediated damage in neurodegenerative disease?
2008
Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease
2016 Standout
Rapid Single-Step Induction of Functional Neurons from Human Pluripotent Stem Cells
2013 StandoutNobel
MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD‐MCI
2011
Screening of innate immune receptors in neurodegenerative diseases: A similar pattern
2007
Parkinsonism, premature menopause, and mitochondrial DNA polymerase γ mutations: clinical and molecular genetic study
2004
Amyloid β-protein toxicity and oxidative stress in Alzheimer's disease
1997
Dopamine D2‐type agonists protect mesencephalic neurons from glutamate neurotoxicity: Mechanisms of neuroprotective treatment against oxidative stress
1998
Lipopolysaccharide Intranigral Injection Induces Inflammatory Reaction and Damage in Nigrostriatal Dopaminergic System
1998
A role of PIEZO1 in iron metabolism in mice and humans
2021 StandoutNobel
Nitric oxide synthase and neuronal vulnerability in parkinson's disease
1996
Aggregated and Monomeric α-Synuclein Bind to the S6′ Proteasomal Protein and Inhibit Proteasomal Function
2003
Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease
1992
Cell-produced α-synuclein oligomers are targeted to, and impair, the 26S proteasome
2008
Direct visualization of Parkinson's disease by in vivo human brain imaging using 7.0T magnetic resonance imaging
2011
Extracellular accumulation of nitric oxide, hydrogen peroxide, and glutamate in astrocytic cultures following glutathione depletion, complex I inhibition, and/or lipopolysaccharide-induced activation
2000
Ferritin for the clinician
2008
The NADH:ubiquinone oxidoreductase (complex I) of respiratory chains
1992 StandoutNobel
Catechol-O-Methyltransferase Inhibitors in Parkinson’s Disease
2015
Oxidative stress in Parkinson's disease
2003 Standout
Dysfunction of rat forebrain astrocytes in culture alters cytokine and neurotrophic factor release
2000
Tumor necrosis factor‐α promoter polymorphism is associated with the risk of Parkinson's disease
2006
Continuous subcutaneous infusion of apomorphine rescues nigro-striatal dopaminergic terminals following MPTP injection in mice
2002
P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury
2003 StandoutNature
Rethinking schizophrenia
2010 StandoutNature
Evidence for mitochondrial dysfunction in Parkinson's disease—a critical appraisal
1994
Oxidative stress as a cause of Parkinson's disease
1991
Depressed mood and executive dysfunction in early Parkinson's disease
2003
Genetic ablation of tumor necrosis factor‐alpha (TNF‐α) and pharmacological inhibition of TNF‐synthesis attenuates MPTP toxicity in mouse striatum
2004
The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats
2007
Peripheral iron metabolism in patients with Parkinson's disease
1994
Caspase-11 Mediates Inflammatory Dopaminergic Cell Death in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson's Disease
2004
Inflammatory Cytokine Gene Polymorphisms and Increased Risk of Parkinson Disease
2007
Role of mitochondria in the etiology and pathogenesis of Parkinson's disease
1995
The Role of Iron in Neurodegeneration
1999
Alzheimer's Disease
2010 Standout
The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it
1992
Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases
2006 StandoutNature
Does structural neuroimaging reveal a disturbance of iron metabolism in Parkinson’s disease? Implications from MRI and TCS studies
2012
Hormesis, cellular stress response and vitagenes as critical determinants in aging and longevity
2011
Sterile inflammation: sensing and reacting to damage
2010 Standout
A Drosophila model of Parkinson's disease
2000 StandoutNature
The role of iron in brain ageing and neurodegenerative disorders
2014 Standout
Association of circulating TNF-α and IL-6 with ageing and parkinsonism
1999
Plasma Ceruloplasmin Ferroxidase Activity Correlates with the Nigral Sonographic Area in Parkinson’s Disease Patients: A Pilot Study
2011
Neostriatal Dopamine Uptake and Reversal of Age‐related Movement Disorders with Dopamine‐Uptake Inhibitorsa
1988
Functional promoter region polymorphism of the proinflammatory chemokine IL-8 gene associates with Parkinson's disease in the Irish
2004
The anterior olfactory nucleus in Parkinson's disease
1995
The Hallmarks of Aging
2013 Standout
Role of TNF-α Receptors in Mice Intoxicated with the Parkinsonian Toxin MPTP
2002
Striatal Dopamine Metabolism in Monoamine Oxidase B‐Deficient Mice : A Brain Dialysis Study
1999
Neural cell adhesion molecule (NCAM) as a quantitative marker in synaptic remodeling
1995
Inflammatory Regulators in Parkinson's Disease: iNOS, Lipocortin-1, and Cyclooxygenases-1 and -2
2000
The epigenetics of aging and neurodegeneration
2015
The importance of glutathione in human disease
2003 Standout
The Inflammatory Reaction Following 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Intoxication in Mouse
1999
Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1β in the substantia nigra
2006
Colonic inflammation in Parkinson's disease
2012
Basal Ganglia Dopamine Receptor Autoradiography and Age‐related Movement Disordersa
1988
Lymphocyte populations in Parkinson's disease and in rat models of parkinsonism
2001
Increased vulnerability of dopaminergic neurons in MPTP‐lesioned interleukin‐6 deficient mice
2002
Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum
2001
Pathways towards and away from Alzheimer's disease
2004 StandoutNature
Nonsteroidal Anti-inflammatory Drugs and the Risk of Parkinson Disease
2003
Microglia as a source and target of cytokines
2002
Cognitive impairment in Parkinson's disease: Tools for diagnosis and assessment
2009
Interleukin-1 polymorphisms associated with increased risk of gastric cancer
2000 StandoutNature
Brain iron metabolism: Neurobiology and neurochemistry
2007
Role of Nerve Growth Factor in Oxidanl Homeostasis: Glutathione Metabolism
1993
Levodopa-Induced Neurotoxicity
1997
Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling
2011 Standout
Reduced dopaminergic binding during aging in the rodent striatum
1980
Neuroimmunological Processes in Parkinson’s Disease and their Relation to α-Synuclein: Microglia as the Referee between Neuronal Processes and Peripheral Immunity
2013
Importance of a novel GABAA receptor subunit for benzodiazepine pharmacology
1989 StandoutNature
Agonism of Peroxisome Proliferator Receptor-Gamma may have Therapeutic Potential for Neuroinflammation and Parkinsons Disease
2007
Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease
2009 Standout
Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease
2014
De novo design of modular protein hydrogels with programmable intra- and extracellular viscoelasticity
2024 StandoutNobel
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
1997 StandoutScience
Aggregation-Induced Emission: Together We Shine, United We Soar!
2015 Standout
Movement Disorders of Aged Rats: Reversal by Dopamine Receptor Stimulation
1979 Science
Evaluation of Dementia Rating Scales in Parkinson’s Disease Dementia
2009
The cell-adhesion G protein-coupled receptor BAI3 is a high-affinity receptor for C1q-like proteins
2011 StandoutNobel
Selective inhibition of NF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease
2007
Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson’s disease
2010
Catalytic Dehydrogenative Cross-Coupling: Forming Carbon−Carbon Bonds by Oxidizing Two Carbon−Hydrogen Bonds
2011 Standout
Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: A case-control study
2006
How neuroinflammation contributes to neurodegeneration
2016 StandoutScience
Theoretical Studies of the Cross-Linking Mechanisms between Cytosine and Tyrosine
2002
Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients
1995
ETIOLOGY AND PATHOGENESIS OF PARKINSON'S DISEASE
1999
The Synaptic Function of α-Synuclein
2015
Inflammation alters the expression of DMT 1, FPN 1 and hepcidin, and it causes iron accumulation in central nervous system cells
2013
Mitochondrial Dysfunction and Type 2 Diabetes
2005 StandoutScience
AETIOLOGY OF PARKINSON'S DISEASE
1983
Mapping of a Gene for Parkinson's Disease to Chromosome 4q21-q23
1996 Science
Role of α-Synuclein Carboxy-Terminus on Fibril Formation in Vitro
2003
The development of mitochondrial medicine.
1994
The MoCA
2010 Standout
The Cholinergic Hypothesis of Geriatric Memory Dysfunction
1982 StandoutScience
Age-related behavioral and neurobiological changes: A review with an emphasis on memory
1981
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
2007 StandoutScience
Highly efficient and large-scale generation of functional dopamine neurons from human embryonic stem cells
2008
Oxidative Stress, Glutamate, and Neurodegenerative Disorders
1993 StandoutScience
Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease
1993
MONOAMINE OXIDASE: From Genes to Behavior
1999
Subcutaneous apomorphine in the treatment of Parkinson's disease.
1990
Altered Glial Function Causes Neuronal Death and Increases Neuronal Susceptibility to 1‐Methyl‐4‐Phenylpyridinium‐ and 6‐Hydroxydopamine‐Induced Toxicity in Astrocytic/Ventral Mesencephalic Co‐Cultures
1999
Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism
1999
The Different Colors of mAbs in Solution
2021
Understanding the GABAA receptor: a chemically gated ion channel
1988
Works of Peter Riederer being referenced
The heterogeneity of Parkinson’s disease
2023
The Effect of Simian Immunodeficiency Virus Infectionin Vitroandin Vivoon the Cytokine Production of Isolated Microglia and Peripheral Macrophages from Rhesus Monkey
1996
Determination of Advanced Glycation End Products in Serum by Fluorescence Spectroscopy and Competitive ELISA
1997
Relating mode of action to clinical practice: Dopaminergic agents in Parkinson's disease
2007
AGES in brain ageing: AGE-inhibitors as neuroprotective and anti-dementia drugs?
2001
Parkinson's disease and depression: evidence for an alteration of the basal limbic system detected by transcranial sonography
1997
Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity
2013
The relevance of preclinical studies for the treatment of Parkinson's disease
2003
A molecular signature in blood identifies early Parkinson’s disease
2012
Oxidative stress: a role in the pathogenesis of Parkinson’s disease
1990
Transition metal‐mediated glycoxidation accelerates cross‐linking of β‐amyloid peptide
2000
Understanding Parkinson's Disease
1997
Antioxidant capacity in postmortem brain tissues of Parkinson’s and Alzheimer’s diseases
2006
Selegiline is neuroprotective in primary brain cultures treated with 1-methyl-4-phenylpyridinium
1996
Cognitive impairment in 873 patients with idiopathic Parkinson's disease
2008
Advanced glycation end products in neurodegeneration: More than early markers of oxidative stress?
1998
Decreased Catalase Activity but Unchanged Superoxide Dismutase Activity in Brains of Patients with Dementia of Alzheimer Type
1995
Selective Insolubility of α-Synuclein in Human Lewy Body Diseases Is Recapitulated in a Transgenic Mouse Model
2001
Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients
1994
Bromocriptine lessens the incidence of mortality in L-Dopa-treated parkinsonian patients: Prado-study discontinued
1992
In vivo detection of iron and neuromelanin by transcranial sonography: A new approach for early detection of substantia nigra damage
2005
Dopaminergic dysbalance in distinct basal ganglia neurocircuits: Implications for the pathophysiology of parkinson’s disease, schizophrenia and attention deficit hyperactivity disorder
2006
Comparison of benzodiazepine receptor binding in membranes from human or rat brain
1985
Monoamine Oxidase Activity and Monoamine Metabolism in Brains of Parkinsonian Patients Treated with l‐Deprenyl
1986
Increased life expectancy resulting from addition of l-deprenyl to Madopar� treatment in Parkinson's disease: A longterm study
1985
Parkinson's disease putamen: Normal concentration of synaptic membrane marker antigens
1982
Biological Aspects of Depression in Parkinson’s Disease
1986
The neurotoxicity of iron and nitric oxide. Relevance to the etiology of Parkinson's disease.
1993
Neurochemical insights into monoamine oxidase inhibitors, with special reference to deprenyl (selegiline)
1983
Brain iron pathways and their relevance to Parkinson's disease
2002
(-)-Deprenyl Leads to Prolongation of L-Dopa Efficacy in Parkinson�s Disease
2015
Neuroprotection by dopamine agonists
1994
The L-DOPA story - an early Japanese contribution
2000
Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes
2004
Normal Mitochondrial Genome in Brain from Patients with Parkinson's Disease and Complex I Defect
1990
Increased synaptic markers in hippocampus of depressed patients
1985
Time course of nigrostriatal degeneration in parkinson's disease
1976
L-deprenyl plus l-phenylalanine in the treatment of depression
1984
IMPLICATIONS OF COMBINED TREATMENT WITH 'MADOPAR' AND L-DEPRENIL IN PARKINSON'S DISEASE
1977